NetworkNewsWire Editorial Coverage: Known as America’s most expensive disease, with an estimated cost to the U.S. economy of $236 billion in 2016, Alzheimer’s disease (AD) affects more than 5.3 million Americans. Over the next 20 years, the number of those afflicted with the disease is expected to double. The forecast is staggering, considering that no effective cure has been found, but the quest for one continues, with India Globalization Capital, Inc. (NYSE: IGC) (IGC Profile), Anavex Life Sciences (NASDAQ: AVXL), Axovant Sciences (NYSE: AXON), AC Immune Ltd. (NASDAQ: ACIU) and Biogen, Inc. (NASDAQ: BIIB) all exploring a variety of approaches to uncover the pathological pathways of this chronic neurodegenerative disease.
It is believed that Alzheimer’s disease is caused by two types of legions in the cerebral cortex and hippocampus: senile plaque composed of the protein beta-amyloid (Aβ plaque), and neurofibrillary tangle, composed of highly phosphorylated Tau protein. The surface of neurons has a protein called APP that is sectioned by enzymes to free up the Aβ protein that is then cleared by the body. In Alzheimer’s patients, however, there is an imbalance whereby Aβ protein is not regulated and builds up abnormally into insoluble fibroles, creating senile plaques.
Currently, India Globalization Capital (IGC) is the only publicly traded pharmaceutical cannabis stock that addresses Alzheimer’s disease, which positions the company with a first-mover advantage in phytocannabinoid-based combination therapy (http://nnw.fm/0QDQz).
The company’s drug candidate, IGC-ADI, works through a molecular pathway that allows low doses of tetrahydrocannabinol (THC) to 1) inhibit Aβ protein production, 2) inhibit Aβ protein aggregation, 3) reduce protein phosphorylation, 4) potentially restore mitochondria function, and 5) potentially redirect the immune system.
IGC’s evidence supporting this theory is based on two studies done on tissue and mice at the University of South Florida (USF). The USF study found 1) THC to be effective at lowering Aβ levels in N2a/AβPPswe cells at extremely low concentrations in a dose-dependent manner over a 48-hour period; 2) that THC directly interacts with Aβ protein, thereby inhibiting aggregation; 3) that THC was effective at lowering both total GSK-3β levels and phosphorylated GSK-3β in a dose-dependent manner at low concentrations; and 4) that low doses of THC can increase mitochondria function. These studies led to the filing of a patent by USF entitled, “THC as a Potential Therapeutic Agent for Alzheimer’s Disease.” IGC acquired the exclusive right to this patent filing and expects to advance the technology and IGC-AD1 through medical trials.
The theory is further supported by a study conducted by researchers at the Salk Institute of Biological Studies, who drew similar conclusions. In June 2016, the Institute, in a news release (http://nnw.fm/E5Ecm) headlined “Cannabinoids remove plaque-forming Alzheimer’s proteins from brain cells,” revealed that its scientists had found preliminary evidence “that tetrahydrocannabinol (THC) and other compounds found in marijuana can promote the cellular removal of amyloid beta, a toxic protein associated with Alzheimer’s disease.”
A look at other approaches in the market emphasize the unique position occupied by IGC, as well as the exciting potential of ongoing research. Anavex Life Sciences (AVXL), for example, is focused on research aimed at treating more than just the symptoms of Alzheimer’s. The company’s lead candidate, Anavex 2-73, recently completed a phase 2a trial in patients with mild to moderate Alzheimer’s disease, showing a favorable safety and bioavailability profile and dose response curve. Early preclinical studies generated a great deal of excitement, because they indicated that Anavex 2-73 could potentially halt or reverse the course of Alzheimer’s disease through restoration of the body’s homeostasis, according to a report (http://nnw.fm/uN7LN).
At Axovant Sciences (AXON), an air of expectation is mounting as the company anxiously awaits the outcome of a phase 3 trial, started in 2015, for its lead Alzheimer’s candidate, intepirdine. Results are expected by the end of September 2017. Axovant’s drug works in conjunction with another Alzheimer’s drug currently in use, donepezil, and acts on the 5HT6 receptor as an antagonist. While donepezil inhibits the loss of acetylcholine, a chemical in the brain that transmits signals, intepirdine appears to increase the production of that vital medium.
In August, AC Immune (ACIU) announced the discovery of new antibodies that target biomarkers other than Aβ and tau. A news release (http://nnw.fm/WA9xS) reports that “These next-generation antibodies were discovered using the company’s proprietary SupraAntigen™ platform, which has already generated four products in clinical development, including crenezumab partnered with Genentech/Roche in Phase 3 for Alzheimer’s.”
Biogen (BIIB) has also joined the quest for an Alzheimer’s elixir. Its experimental drug to treat the condition, aducanumab, is now in pivotal trials. The company’s valuation soared by more than a billion dollars after analysts at Goldman Sachs (NYSE: GS) added it to their Equity Conviction List, according to the Boston Business Journal (http://nnw.fm/HlL7E).
These efforts to defeat Alzheimer’s are fueled by compelling incentives. Some 5.5 million Americans suffer from the malady, which kills more than breast cancer and prostate cancer combined. The market potential of a remedy has been estimated at over $5 billion, putting IGC at a sweet spot in the conjecture of the medicinal applications of THC and disease treatment.
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
DISCLAIMER: NetworkNewsWire (NNW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by NNW are solely those of NNW. Readers of this Article and content agree that they cannot and will not seek to hold liable NNW for any investment decisions by their readers or subscribers. NNW are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author, and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, NNW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment.
NNW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and NNW undertake no obligation to update such statements.